Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Equity Average: 2013-2025

Historic Equity Average for Veracyte (VCYT) over the last 12 years, with Sep 2025 value amounting to $1.2 billion.

  • Veracyte's Equity Average rose 7.37% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 7.37%. This contributed to the annual value of $1.1 billion for FY2024, which is 4.75% up from last year.
  • Latest data reveals that Veracyte reported Equity Average of $1.2 billion as of Q3 2025, which was up 2.60% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Equity Average peaked at $1.2 billion during Q3 2025, and registered a low of $697.7 million during Q1 2021.
  • For the 3-year period, Veracyte's Equity Average averaged around $1.1 billion, with its median value being $1.1 billion (2024).
  • In the last 5 years, Veracyte's Equity Average surged by 326.09% in 2021 and then fell by 3.64% in 2022.
  • Veracyte's Equity Average (Quarterly) stood at $1.1 billion in 2021, then decreased by 3.64% to $1.1 billion in 2022, then dropped by 1.19% to $1.0 billion in 2023, then climbed by 12.10% to $1.2 billion in 2024, then grew by 7.37% to $1.2 billion in 2025.
  • Its Equity Average stands at $1.2 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.